chlorprothixene

Trade name: taractan

Small moleculeapproved

Approved

Mar 23, 1962

Chlorprothixene (Taractan, Tarasan, Truxal) is a thioxanthine derivative developed by Lundbeck for the treatment of psychotic disorders. The drug exerts its activity by binding to and inhibiting serotonin receptors, dopamine receptors, muscarinic acetylcholine receptor, histamine H1 receptor and alpha1-adrenergic receptor. — NCATS

Clinical trial activity

1 trials · 1 clinical orgs · 1 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Jan 1, 2015 (NCT02374567)

Timeline

1960s

Mar 23, 1962
Roche — Earliest FDA Approval
Mar 23, 1962
Roche — NDA Organization

2010s

Jan 1, 2015
Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Psychotic Disorders

Studied for

Mechanism of action

Dopamine D3 receptorANTAGONIST
DRD3 antagonist
- D(3) dopamine receptor (DRD3) ↗
Serotonin 2c (5-HT2c) receptorANTAGONIST
HTR2C antagonist
- 5-hydroxytryptamine receptor 2C (HTR2C) ↗
Serotonin 2a (5-HT2a) receptorANTAGONIST
HTR2A antagonist
- 5-hydroxytryptamine receptor 2A (HTR2A) ↗
Dopamine D2 receptorANTAGONIST
DRD2 antagonist
- D(2) dopamine receptor (DRD2) ↗

Approval history

approvedMar 23, 1962

Chemistry & pharmacology

Loading structure…

SMILES

CN(C)CC/C=C1/c2ccccc2Sc2ccc(Cl)cc21

Mol. weight: 315.87 g/mol
Lipinski Ro5: 1 violation(s)
Rule of 3: No
Chirality: Achiral Molecule
Inorganic: No
Polymer: No
Delivery: Oral, Parenteral
Availability: Discontinued

Oral

Yes

Parenteral

Yes

Topical

Sources

Also known as

alpha-chlorprothixene
alpha-chlorprothixene
chlorprothixen
chlorprothixen
chlorprothixen
chlorprothixene
chlorprothixene
chlorprothixene
chlorprothixene
chlorprothixene
chlorprothixene
chlorprothixene
chlorprothixene
chlorprothixene
chlorprothixene
chlorprothixene
chlorprothixene
chlorprothixene hcl
chlorprothixene hydrochloride
chlorprothixine
chlorprothixine
chlorprotixen
chlorprotixen
chlorprotixen
chlorprotixene
chlorprotixene
chlorprotixene
chlorprotixine
chlorprotixine
chlothixen
chlothixen
chlothixen
chorprothixene
n-714
n-714
ro-40403
ro-40403
taractan
taractan
taractan
taractan
truxal
truxal

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT02374567	Phase 3	Jan 1, 2015	Gottfried Wilhelm Leibniz Universität Hannover

Showing 1 of 1 trials

Page 1 / 1

Organizations

Research & Development (1)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Gottfried Wilhelm Leibniz Universität Hannover	Academic/Hospital	1	1	1	2015

1 organizations

Page 1 / 1

Marketing (1)

Organization	Org type	Relationship	Date
Roche	For profit	NDA	Mar 23, 1962